Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia

Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome

(2013) Johann K. Hitzler et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

(2013) L. Chaudhuri et al.   HAEMATOLOGICA

Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality

(2013) A. A. Van Linden et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

(2013) A. D. Guertin et al.   MOLECULAR CANCER THERAPEUTICS

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas

(2013) Jenny M. Kreahling et al.   PLoS One

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

(2013) Chengzhi Xie et al.   PLoS One

RNAi screening of the kinome with cytarabine in leukemias

(2012) R. Tibes et al.   BLOOD

Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome

(2012) T. Taga et al.   BLOOD

Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

(2012) H. Beck et al.   MOLECULAR AND CELLULAR BIOLOGY

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia

(2010) C. Xie et al.   CLINICAL CANCER RESEARCH

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase

(2010) Halfdan Beck et al.   JOURNAL OF CELL BIOLOGY

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia

(2009) H. Edwards et al.   BLOOD

Down Syndrome and Malignancies: A Unique Clinical Relationship

(2009) Ana C. Xavier et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421

(2008) Maureen M. O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY